openPR Logo
Press release

Growth of Thin Film Drug Manufacturing Market is very Promising due to Increasing Acceptance of this Technology by the Pharmaceutical Companies

10-13-2016 09:32 AM CET | Health & Medicine

Press release from: TMR - Research Reports

Growth of Thin Film Drug Manufacturing Market is very Promising

Thin film drug manufacturing involves drugs to be incorporated into thin polymeric films so that the drug gets wider absorption. Thin film formulation is a recent advancement in the drug delivery fields. From pharmacological point of view, thin film drug manufacturing offers distinct advantage due to direct systemic absorption. This prevents degradation of drug into the gastrointestinal tract and also avoids first pass effect.

Download Exclusive Sample of this Report: http://bit.ly/2de6DsZ

Another advantage of thin films drugs is that it dissolves rapidly therefore increases the patient compliance. The future growth for thin film drug manufacturing market is very promising due to increasing acceptance of this technology by the pharmaceutical companies. The growth will be further fuelled by both the generic and branded drug manufacturers launching their drugs in thin film formulation. The factors which currently restrain the market are small amount (less than 30mg) of drugs that can be administered and the inconsistent drug release pattern from these formulations.

The global thin film drug manufacturing market is segmented into edible oral films, fully dissolving dental/buccal films and dermal films. Dermal thin films include advanced wound dressings and temporary skin plaster. The global thin film drug manufacturing market is expected to expand in the coming years owing to several advantages over the conventional routes of drug deliveries.

Presently, over-the-counter thin films are available in the market for applications such as pain management and motion sickness. Transdermal patches have been already commercialized which use thin polymer films for drug delivery. Some of the popular thin film products include Listerine Pocketpaks® (Pfizer, Inc.) oral care strips for mouth ulcers, TheraFlu Thin Strips (Multi Symptom and Long Acting Cough, Novartis Consumer Health, Inc.), Sudafed PE Quick Dissolving Strips (Wolters Kluwer Healthc, Inc.) for congestion, Triaminic (Novartis AG) for allergy, Gas-x Strips (Novartis AG) as antiflatulant, Suppress (InnoZen, Inc.) for cough, Klonopin wafers (Solvay Pharmaceuticals) for anxiety, and for Chloraseptic (Prestige Brands, Inc.) sore throat.

Today thin films containing drugs is an accepted technology for systemic delivery of APIs for over-the-counter (OTC) medications while this technology is under development stages for prescription drugs. The companies which have been in the market manufacturing the formulations for transdermal drug delivery using polymer coatings to active pharmaceutical ingredients (APIs) are now capitalizing this new opportunity.

These companies therefore have a competitive advantage over the new entrants into market. Furthermore, the leading pharmaceutical companies have also focused on partnering with technology companies rather than investing in the technology. For instance, Reckitt Benckiser Pharmaceuticals Inc. has collaborated with MonoSol Rx, LLC, for utilizing latter’s proprietary PharmFilm technology for delivering drugs. This collaboration has led to successful product Suboxone (buprenorphine and naloxone) sublingual film that has been approved by FDA in 2010. Similarly, Strativa Pharmaceuticals has developed Zuplenz (ondansetron oral soluble film) using the same technology from MonoSol Rx, LLC.

Several companies are adopting these technologies to bring more formulations which include oral route as well. Presently, the global market for thin film drug manufacturing is relatively immature with little number of products in the market. However, in the coming years the number of players in market will increase the competition and expand the global market. Some of the important players in the global thin film drug manufacturing market include Reckitt Benckiser plc, Pfizer Inc., Solvay Pharmaceuticals, Novartis Consumer Health, Inc., Wolters Kluwer Healthc, Inc., InnoZen, Inc.

Browse Research Report: http://bit.ly/2eucoIl

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Growth of Thin Film Drug Manufacturing Market is very Promising due to Increasing Acceptance of this Technology by the Pharmaceutical Companies here

News-ID: 371993 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Novartis

Pazopanib Market Analysis By Top Keyplayers - Novartis, GlaxoSmithKline, Novarti …
The "Pazopanib Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023. Growing Demand and Growth Potential in the Global Pazopanib Market, 2024-2031 Verified Market Research's most recent report, "Pazopanib Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030," provides an in-depth examination of the
Onychomycosis Market to Register Incremental Growth During the Forecast Period ( …
DelveInsight's "Onychomycosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Onychomycosis, historical and forecasted epidemiology as well as the Onychomycosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Onychomycosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Onychomycosis Market Forecast https://www.delveinsight.com/sample-request/onychomycosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key facts of the Onychomycosis
(2023-2031) Acromegaly Market | Novartis AG, Ipsen Pharma
[100 pages] Report "Acromegaly Market" detailed analysis of a business is mainly segmented by Application, by Type, Region (North America, Europe, Asia-Pacific, South America, and Middle East & Africa), manufacture and Forecast to 2031. "Final Report will add the analysis of the impact of COVID-19 on this industry." Global "Acromegaly Market" report analyses the best market prospects and lists the characteristics that are and will continue to propel the development of the
Rydapt Market 2020 Clinical Analysis – Novartis
Global Rydapt Market Growth 2020-2025 The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Rydapt Market on the basis of stating current situation of the industry in 2020. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought
Global HER2-negative breast cancer Treatment Market to 2025| AstraZeneca, Bristo …
Researchmoz added Most up-to-date research on "Global HER2-negative breast cancer Treatment Market Size, Status and Forecast 2019-2025" to its huge collection of research reports. HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein. In 2018, the global HER2-negative breast cancer Treatment
Nilotinib Market Report 2018 – 2023: Novartis
The Study Paper in this Global Nilotinib Market includes Novartis. Get Free Sample Brochure of Nilotinib Market spread across [142 pages] @ https://www.marketgrowthinsight.com/sample/4896 Unbiased perspective on intangible aspects such as key challenges, threats, new entrants as well as strengths and weaknesses of the prominent vendors too are